NCT06958939View on ClinicalTrials.gov

The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

August 30, 2026

Conditions
Myasthenia Gravis, Generalized
Interventions
DRUG

Dose level 1 group

1.0 × 10e6/kg S103 CAR-T cells

DRUG

Dose level 2 group

2.0 × 10e6/kg S103 CAR-T cells

DRUG

Dose level 3 group

4.0 × 10e6/kg S103 CAR-T cells

DRUG

Dose level 4 group

8.0 × 10e6/kg S103 CAR-T cells

Trial Locations (1)

710038

The Second Affiliated Hospital of Air Force Medical University, Xi'an

All Listed Sponsors
collaborator

Hebei Senlang Biotechnology Co., LTD

UNKNOWN

lead

Ting Chang, MD

OTHER

NCT06958939 - The Safety and Efficacy of S103 in the Treatment of Refractory Generalized Myasthenia Gravis | Biotech Hunter | Biotech Hunter